Effect of pravastatin on markers of endothelial activation in dialysis patients

Nephrology

Volumn 12, Issue 3, 2007, Pages 234-238

  Jeffs, Lisa S ^a   Skilton, Frances ^a   Nitschke, Jodie ^a   Bannister, Kym M ^a   Faull, Randall J ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Endothelial activation; High sensitivity C reactive protein; Interleukin 6; Lipids; Pravastatin; Soluble adhesion molecules

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADULT; AGED; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; LIPIDS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PILOT PROJECTS; PRAVASTATIN;

EID: 34248214076     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00766.x     Document Type: Article

References (23)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998 9 : S16 23.
2. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000 58 : 353 62.
3. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003 63 : 793 808.
4. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004 291 : 451 9.
5. Ross R. Atherosclerosis - An inflammatory disease. N. Engl. J. Med. 1999 340 : 115 26.
6. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 55 : 648 58.
7. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998 79 : 399 407.
8. Papayianni A, Alexopoulos E, Giamalis P et al. Circulating levels of ICAM-1, VCAM-1 and MCP-1 are increased in haemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol. Dial. Transplant. 2002 17 : 435 41.
9. Bolton CH, Downs LG, Victory JGG et al. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 2001 16 : 1189 97.
10. Faull RJ. Adhesion molecules in health and disease. Aust. NZ. J. Med. 1995 25 : 720 30.
11. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am. J. Kidney Dis. 1998 31 : 93 100.
12. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive Protein. Circulation 1999 100 : 230 35.
13. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein in haemodialysis patients. Am. J. Kidney Dis. 2002 39 : 1213 17.
14. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol. Dial. Transplant. 2002 17 : 1513 17.
15. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does Atorvastatin influence serum C-reactive Protein levels in patients on long-term hemodialysis? Am. J. Kidney Dis. 2004 43 : 471 8.
16. Navarro JF, Mora C, Muros M, Garcia-Idoate G. Effects of Atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin. Pract. 2003 95 : c128 35.
17. Ikejiri A, Hirano T, Murayama S et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004 53 : 1113 17.
18. Tsirpanlis G, Boufidou F, Manganas S et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level. Inflammation in hemodialysis patients. Blood Purif. 2004 22 : 518 24.
19. van den Akker JM, Bredie SJH, Diepenveen SHA, van Tits LJH, Stalenhoef FH, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: Effect on lipoproteins, C-reactive protein and in vivo oxidized LDL. J. Nephrol. 2003 16 : 238 44.
20. Malyszko J, Malyszko JS, Hryszko T, Brzosko B, Mysliwiec M. Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis. Int. J. Tissue React. 2002 XXIV : 111 15.
21. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul. Fibrinolysis 2004 15 : 463 7.
22. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and the risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003 107 : 1486 91.
23. Basso F, Lowe G, Rumley A, McMahon AD, Humphries SE. Interleukin-6- 174G>C polymorphism and risk of coronary heart disease in west of Scotland coronary prevention study (WOSCOPS). Arterioscler. Thromb. Vasc. Biol. 2002 22 : 599 604.